CBIO (Crescent Biopharma) EBIT: $-159.00 Mil (TTM As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma EBIT?

Crescent Biopharma CBIO +9.24% 10 EBIT is $-159.00 Mil as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-23.28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-159.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Crescent Biopharma's annualized ROC % for the quarter that ended in Mar. 2026 was -612.43%. Crescent Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -4,035.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Crescent Biopharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -48.45%.

Crescent Biopharma  (NAS:CBIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Crescent Biopharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-98.916 * ( 1 - 0% )/( (18.35 + 13.953)/ 2 )
=-98.916/16.1515
=-612.43 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=240.293 - 21.36 - ( 213.192 - max(0, 36.072 - 236.655+213.192))
=18.35

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=199.13 - 3.807 - ( 189.163 - max(0, 14.193 - 195.563+189.163))
=13.953

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Crescent Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-93.132/( ( (2.315 + max(-12.174, 0)) + (2.301 + max(-7.34, 0)) )/ 2 )
=-93.132/( ( 2.315 + 2.301 )/ 2 )
=-93.132/2.308
=-4,035.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18 + 0 + 5.463) - (21.36 + 4.156 + 10.121)
=-12.174

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.4) - (3.807 + 3.117 + 6.816)
=-7.34

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Crescent Biopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-159.004/328.168
=-48.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma EBIT Related Terms

Crescent Biopharma EBIT Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma EBIT Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
EBIT
0.00 -149.76

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial -14.04 -20.72 -24.61 -90.40 -23.28

CBIO vs RIGL, GYRE, TRAX: EBIT Comparison

For the Biotechnology subindustry, Crescent Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's EV-to-EBIT falls into.


CBIO
10GF Score
Crescent Biopharma Inc CBIO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-159.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-159.00 Mil mean?
Crescent Biopharma (CBIO) has a EBIT of $-159.00 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Crescent Biopharma.
Is Crescent Biopharma's EBIT too high?
Crescent Biopharma's current EBIT is $-159.00 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's EBIT compare to RIGL and GYRE?
Crescent Biopharma's EBIT of $-159.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Crescent Biopharma. Crescent Biopharma's current EBIT is $-159.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current EBIT of $-159.00 Mil. The current EBIT is $-159.00 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current EBIT is $-159.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price